GoAI
Get started
Neuronetics, Inc. logo

Neuronetics, Inc.

STIM

NASDAQHealthcareMedical - Devices

Open in GoAI

Previous close

$3.00

−$0.09 · -2.91%

Aug 21, 4:00 PM ET

STIM company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

68

Undervalued

Momentum

57

Neutral

Sentiment

53

Mixed

Risk resilience

31

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Neuronetics, Inc. functions as a medical technology enterprise with commercialized products, specializing in the creation, enhancement, and global distribution of solutions for individuals experiencing neurohealth conditions, both within the U.S. and abroad. The company's flagship product is the NeuroStar Advanced Therapy System, an in-office, non-surgical, and non-pharmaceutical treatment option available for adult patients diagnosed with major depressive disorder. This sophisticated system utilizes transcranial magnetic stimulation (TMS) to generate a pulsed magnetic field, similar in strength to an MRI, which subsequently induces electrical currents. These currents are specifically engineered to activate brain areas that are key to mood regulation. Neuronetics distributes its offerings directly to psychiatrists through its dedicated sales and client support personnel. Established in 2001, the company's corporate headquarters are situated in Malvern, Pennsylvania.

Industry
Medical - Devices
Sector
Healthcare
Headquarters
US
CEO
Daniel L. Reuvers
Listed since
Jun 28, 2018
Employees
658

Market position

Day range

Current $3.00

52-week range

Current $3.00

Open
$3.08
Previous close
$3.09
Volume
1.03M
0.43× average
Average volume
2.41M
Average daily volume
Market cap
208.76M USD
Beta
1.12
Market reference 1
50-day average
$1.9402
+54.62% above average
200-day average
$1.6626
+80.44% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
147.18M USD
EV / EBITDA
-5.43×
Earnings yield
-42.85%
Free cash flow yield
-23.27%

Profitability & efficiency

Return on equity
-174.27%
Return on assets
-27.55%
Return on invested capital
-26.96%

Financial health

Current ratio
2.02×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends93%38%-17%-72%Gross margin, FY2021: 78.93%Gross margin, FY2022: 76.26%Gross margin, FY2023: 72.47%Gross margin, FY2024: 72.32%Gross margin, FY2025: 48.48%Operating margin, FY2021: -49.83%Operating margin, FY2022: -53.85%Operating margin, FY2023: -42.82%Operating margin, FY2024: -46.15%Operating margin, FY2025: -21.08%Net margin, FY2021: -56.39%Net margin, FY2022: -56.99%Net margin, FY2023: -42.31%Net margin, FY2024: -58.36%Net margin, FY2025: -26.15%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 78.93%. Gross margin FY2022 76.26%. Gross margin FY2023 72.47%. Gross margin FY2024 72.32%. Gross margin FY2025 48.48%. Operating margin FY2021 -49.83%. Operating margin FY2022 -53.85%. Operating margin FY2023 -42.82%. Operating margin FY2024 -46.15%. Operating margin FY2025 -21.08%. Net margin FY2021 -56.39%. Net margin FY2022 -56.99%. Net margin FY2023 -42.31%. Net margin FY2024 -58.36%. Net margin FY2025 -26.15%.

Income trends

Revenue

149.16M USD+99.17%

Operating income

−31.44M USD+9.05%

Net income

−39M USD+10.78%
Income trends across reported periods168.44M USD91.3M USD14.15M USD−62.99M USDRevenue, FY2021: 55.31M USDRevenue, FY2022: 65.21M USDRevenue, FY2023: 71.35M USDRevenue, FY2024: 74.89M USDRevenue, FY2025: 149.16M USDOperating income, FY2021: −27.56M USDOperating income, FY2022: −35.11M USDOperating income, FY2023: −30.55M USDOperating income, FY2024: −34.56M USDOperating income, FY2025: −31.44M USDNet income, FY2021: −31.19M USDNet income, FY2022: −37.16M USDNet income, FY2023: −30.19M USDNet income, FY2024: −43.71M USDNet income, FY2025: −39M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 55.31M USD. Revenue FY2022 65.21M USD. Revenue FY2023 71.35M USD. Revenue FY2024 74.89M USD. Revenue FY2025 149.16M USD. Operating income FY2021 −27.56M USD. Operating income FY2022 −35.11M USD. Operating income FY2023 −30.55M USD. Operating income FY2024 −34.56M USD. Operating income FY2025 −31.44M USD. Net income FY2021 −31.19M USD. Net income FY2022 −37.16M USD. Net income FY2023 −30.19M USD. Net income FY2024 −43.71M USD. Net income FY2025 −39M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue149.16M USD74.89M USD71.35M USD65.21M USD55.31M USD
Cost of goods sold76.85M USD20.73M USD19.64M USD15.48M USD11.65M USD
Gross profit72.31M USD54.16M USD51.71M USD49.72M USD43.66M USD
Research and development6.58M USD12.77M USD9.52M USD9.34M USD7.92M USD
Selling, general, and administrative97.16M USD75.95M USD72.74M USD75.5M USD63.3M USD
Operating expenses103.74M USD88.72M USD82.26M USD84.83M USD71.22M USD
Interest income——24K USD——
Interest expense8.42M USD7.29M USD5.42M USD3.6M USD3.3M USD
Depreciation and amortization3.47M USD2.07M USD2.01M USD1.65M USD1.06M USD
Operating income−31.44M USD−34.56M USD−30.55M USD−35.11M USD−27.56M USD
Net income−39M USD−43.71M USD−30.19M USD−37.16M USD−31.19M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
45%
5 beats, 6 misses, 0 met estimates
Average EPS surprise
-15.53%
11 comparable reports
Latest EPS result
-0.05
Estimate -0.12 · Beat by 59.35%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.04-0.15-0.26-0.37Q1 '25MissQ2 '25MissQ3 '25MissQ4 '25MissQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 4, 2025: actual -0.33, estimate -0.26, surprise -26.92%, Miss. Q2 2025, reported May 6, 2025: actual -0.21, estimate -0.13, surprise -61.54%, Miss. Q3 2025, reported Aug 5, 2025: actual -0.15, estimate -0.08, surprise -87.50%, Miss. Q4 2025, reported Nov 4, 2025: actual -0.13, estimate -0.12, surprise -8.33%, Miss. Q1 2026, reported Mar 17, 2026: actual -0.1, estimate -0.12, surprise +16.67%, Beat. Q2 2026, reported May 5, 2026: actual -0.16, estimate -0.17, surprise +5.88%, Beat. Q3 2026, reported Aug 11, 2026: actual -0.05, estimate -0.123, surprise +59.35%, Beat. Q4 2026, reported Nov 3, 2026: actual —, estimate -0.09, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates43.45M35.91M28.36M20.82MQ1 '25MissQ2 '25MissQ3 '25BeatQ4 '25MissQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 4, 2025: actual 22.49M USD, estimate 28.8M USD, surprise -21.90%, Miss. Q2 2025, reported May 6, 2025: actual 31.98M USD, estimate 36.6M USD, surprise -12.63%, Miss. Q3 2025, reported Aug 5, 2025: actual 38.11M USD, estimate 37.85M USD, surprise +0.69%, Beat. Q4 2025, reported Nov 4, 2025: actual 37.3M USD, estimate 37.85M USD, surprise -1.45%, Miss. Q1 2026, reported Mar 17, 2026: actual 41.78M USD, estimate 40.67M USD, surprise +2.72%, Beat. Q2 2026, reported May 5, 2026: actual 34.45M USD, estimate 34.17M USD, surprise +0.84%, Beat. Q3 2026, reported Aug 11, 2026: actual 41.57M USD, estimate 40.17M USD, surprise +3.47%, Beat. Q4 2026, reported Nov 3, 2026: actual —, estimate 40.33M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$5.00

66.67% upside
Past 12 months12-month forecastHigh $5.00Average $5.00Low $5.00

Rating distribution

7 ratings
Strong buy00%
Buy686%
Hold114%
Sell00%
Strong sell00%

STIM peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding STIM

Funds reporting this stock among their holdings, ordered by reported position size.

AdvisorShares Psychedelics ETF logoAdvisorShares Psychedelics ETFPSIL
Market value
2.59M
Weight
4.49%
AUM
57.72M USD
Expense ratio
1.84%
Price / 1D
$25.86-0.35%
Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
2.09M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
948.35K
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
292.7K
Weight
0.02%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$198.39+1.10%
Invesco NASDAQ Future Gen 200 ETF logoInvesco NASDAQ Future Gen 200 ETFQQQS
Market value
224.64K
Weight
0.99%
AUM
22.98M USD
Expense ratio
0.20%
Price / 1D
$45.0826+1.10%

Continue in GoAI

Research STIM

research.disclaimer